Literature DB >> 12091878

Hyporesponsiveness to vaccination with Borrelia burgdorferi OspA in humans and in TLR1- and TLR2-deficient mice.

Lena Alexopoulou1, Venetta Thomas, Markus Schnare, Yves Lobet, Juan Anguita, Robert T Schoen, Ruslan Medzhitov, Erol Fikrig, Richard A Flavell.   

Abstract

The Lyme disease vaccine is based on the outer-surface lipoprotein (OspA) of the pathogen Borrelia burgdorferi, and 95% of vaccine recipients develop substantial titers of antibodies against OspA. Here, we identified seven individuals with very low antibody titers after vaccination (low responders). The macrophages of low responders produced less tumor necrosis factor-alpha and interleukin-6 after OspA stimulation and had lower cell-surface expression of Toll-like receptor (TLR) 1 as compared to normal cells, but normal expression of TLR2. TLRs activate innate responses to pathogens, and TLR2 recognizes lipoproteins and peptidoglycan (PGN). After OspA immunization, mice genetically deficient in either TLR2 (TLR2(-/-)) or TLR1 (TLR1(-/-)) produced low titers of antibodies against OspA. Notably, macrophages from TLR2(-/-) mice were unresponsive to OspA and PGN, whereas those from TLR1(-/-) mice responded normally to PGN but not to OspA. These data indicate that TLR1 and TLR2 are required for lipoprotein recognition and that defects in the TLR1/2 signaling pathway may account for human hyporesponsiveness to OspA vaccination.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12091878     DOI: 10.1038/nm732

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  142 in total

1.  TLR2 activation inhibits embryonic neural progenitor cell proliferation.

Authors:  Eitan Okun; Kathleen J Griffioen; Tae Gen Son; Jong-Hwan Lee; Nicholas J Roberts; Mohamed R Mughal; Emmette Hutchison; Aiwu Cheng; Thiruma V Arumugam; Justin D Lathia; Henriette van Praag; Mark P Mattson
Journal:  J Neurochem       Date:  2010-04-29       Impact factor: 5.372

2.  A novel aminosaccharide compound blocks immune responses by Toll-like receptors and nucleotide-binding domain, leucine-rich repeat proteins.

Authors:  Kyoung-Hee Lee; Yuen-Joyce Liu; Amlan Biswas; Chikako Ogawa; Koichi S Kobayashi
Journal:  J Biol Chem       Date:  2010-12-07       Impact factor: 5.157

Review 3.  Immunogenomics and systems biology of vaccines.

Authors:  Luigi Buonaguro; Bali Pulendran
Journal:  Immunol Rev       Date:  2011-01       Impact factor: 12.988

Review 4.  Use of defined TLR ligands as adjuvants within human vaccines.

Authors:  Malcolm S Duthie; Hillarie Plessner Windish; Christopher B Fox; Steven G Reed
Journal:  Immunol Rev       Date:  2011-01       Impact factor: 12.988

Review 5.  Dysregulation of human Toll-like receptor function in aging.

Authors:  Albert C Shaw; Alexander Panda; Samit R Joshi; Feng Qian; Heather G Allore; Ruth R Montgomery
Journal:  Ageing Res Rev       Date:  2010-11-10       Impact factor: 10.895

Review 6.  Design considerations for liposomal vaccines: influence of formulation parameters on antibody and cell-mediated immune responses to liposome associated antigens.

Authors:  Douglas S Watson; Aaron N Endsley; Leaf Huang
Journal:  Vaccine       Date:  2012-02-02       Impact factor: 3.641

7.  Novel toll-like receptor 2 ligands for targeted pancreatic cancer imaging and immunotherapy.

Authors:  Amanda Shanks Huynh; Woo Jin Chung; Hyun-Il Cho; Valerie E Moberg; Esteban Celis; David L Morse; Josef Vagner
Journal:  J Med Chem       Date:  2012-11-08       Impact factor: 7.446

8.  Diprovocims: A New and Exceptionally Potent Class of Toll-like Receptor Agonists.

Authors:  Matthew D Morin; Ying Wang; Brian T Jones; Yuto Mifune; Lijing Su; Hexin Shi; Eva Marie Y Moresco; Hong Zhang; Bruce Beutler; Dale L Boger
Journal:  J Am Chem Soc       Date:  2018-10-16       Impact factor: 15.419

9.  Evaluation of vaccine-induced antibody responses: impact of new technologies.

Authors:  Daniel J Zaccaro; Diane K Wagener; Carol C Whisnant; Herman F Staats
Journal:  Vaccine       Date:  2013-04-11       Impact factor: 3.641

10.  Protective niche for Borrelia burgdorferi to evade humoral immunity.

Authors:  Fang Ting Liang; Eric L Brown; Tian Wang; Renato V Iozzo; Erol Fikrig
Journal:  Am J Pathol       Date:  2004-09       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.